Speaker Profile

Ph.D., CEO, Biological Dynamics

Raj built the company based on technology he developed for his dissertation, where he pioneered the use of AC Electrokinetics for the purpose of blood-based diagnosis. His passion and conviction have led Biological Dynamics through multiple funding rounds, securing $75 million to develop platforms to analyze biomarkers and study feasible applications for early diagnosis of cancer, tuberculosis, and Alzheimer’s disease. Raj founded Biological Dynamics to revolutionize the approach toward the diagnosis and treatment of high burden diseases—the manifestation of his desire to help people with cancer and save lives. Under Raj's vision and guidance, Biological Dynamics has transformed from concept to early-stage startup and is now one of the most innovative diagnostic companies in Southern California, with 47 patents granted (20 in the U.S.) and 44 pending. Raj has published several papers on AC Electrokinetics and was previously named to the Top 30 Under 30 Scientists by Forbes magazine.

Liquid Biopsy Showcase:
Biological Dynamics

Biological Dynamics, Inc. is a healthcare company committed to improving global health outcomes by detecting diseases at their earliest stages. The company's proprietary platform simplifies access to native-state biomarkers and nanoparticles, enabling differentiated multiomics applications.

Exosome Classifier For Early-Stage Cancer Detection
Biological Dynamics is advancing early cancer detection by leveraging its Verita™ platform to capture and analyze exosomes from early-stage (I/II) cancer patient samples. Analysis of exosomal biomarkers enables highly sensitive and specific cancer detection, potentially allowing earlier cancer intervention.

 Session Abstract – PMWC 2022 Silicon Valley

The PMWC 2022 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).